United States: Federal Circuit Invalidates Galderma Differin Patents

In Galderma Laboratories v. Tolmar, Inc., the Federal Circuit reversed the district court's findings that the Orange Book-listed patents for Galderma's Differin® 0.3% gel product were not invalid as obvious. In so doing, the Federal Circuit took a narrow view of "unexpected results" that Judge Newman warns may "disincentivize" improvement patents in the field of medicine.

The Patents At Issue

The patents at issue were the five Orange Book-listed patents for Galderma's Differin® 0.3% gel product: U.S. Patent No. 7,579,377; U.S. Patent No. 7,737,181; U.S. Patent No. 7,834,060; U.S. Patent No. 7,838,558; and U.S. Patent No. 7,868,044.

The Federal Circuit identified claim 5 of the '558 patent are representative:

5. A topically applicable pharmaceutical composition comprising 0.3% by weight of [adapalene] relative to the total weight of the composition, effective for the treatment of acne, formulated into a topically applicable, pharmaceutically acceptable medium therefor, said composition being in the form of a topically applicable, pharmaceutically acceptable aqueous gel comprising at least one carbomer gelling agent and wherein the sole anti acne ingredient is adapalene.

The ANDA Litigation

The case stemmed from Tolmar's filing of an Abbreviated New Drug Application ("ANDA") seeking FDA approval of a generic version of Galderma's Differin® Gel 0.3% product. As noted by the Federal Circuit, the product "is a topical medication containing 0.3% by weight adapalene approved for the treatment of acne." Galderma brought suit in the U.S. District Court for the District of Delaware, which ultimately ruled in Galderma's favor.

The Asserted Prior Art

Tolmar asserted that the patents were obvious in view of three primary references: U.S. Patent No. 4,717,720 (referred to by the Federal Circuit as the "Shroot '720 patent"), U.S. Reissue Patent No. 34,440 (referred to by the Federal Circuit as the "Shroot '440 patent"), and the Differin® 0.1% Gel Data Sheet (referred to by the Federal Circuit as the "Data Sheet"). The 0.1% gel product had been approved about 10 years before the 0.3% gel product, and the Shroot patents had been listed in the Orange Book for the 0.1% gel product until they expired.

According to the Federal Circuit, the Shroot patents disclosed adapalene for use in treating acne, at concentrations "preferably between 0.01 and 1 weight percent," with examples of compositions with concentrations of 0.001%, 0.1%, and 1%. The Data Sheet disclosed the formulation for the 0.1% gel product, which includes inactive ingredients recited in the asserted claims, except that it listed "poloxamer 182," while certain asserted claims recited "poloxamer 124." (The district court determined that the two polaxamers were equivalent.)

Tolmar also cited other references testing a 0.3% adapalene composition in an animal model and disclosing a 0.3% adapalene composition for other purposes "without intolerable irritability."

The Federal Circuit Decision

The Federal Circuit decision was authored by Judge Prost and joined by Judge Bryson. Judge Newman authored a dissenting opinion.

Judge Prost begins her analysis with this summary statement:

Tolmar presents an obviousness case that is both straightforward and potent.

According to Judge Prost, because the prior art disclosed a range of adapalene concentrations that encompassed the claimed 0.3% amount, "the burden of production falls upon the patentee to come forward with evidence that (1) the prior art taught away from the claimed invention; (2) there were new and unexpected results relative to the prior art; or (3) there are other pertinent secondary considerations." Still, the "ultimate burden of proving obviousness rests with Tolmar."

No Teaching Away

Although the district court found "teaching away" in the discussion of the "dose-dependent increase in side effects," the Federal Circuit majority disagreed, because there was no teaching "that increasing the concentration to 0.3% would be unproductive," or "that the side effects would be serious enough to dissuade the development of a 0.3% adapalene product."

Although the district court found "teaching away" in the discussion of the 0.1% product as "optimal," the Federal Circuit majority disagreed, based on the principle that "[a] teaching that a composition may be optimal or standard does not criticize, discredit, or otherwise discourage investigation into other compositions."

Non-Probative Unexpected Results

While the district court found unexpected results in the "comparable tolerability" of the 0.1% and 0.3% products, the Federal Circuit majority determined that these unexpected results were "not probative of nonobviousness." In so doing, the majority drew a distinction between results that reflect a difference in degree(not probative) versus results that reflect a difference in kind(probative).

Unexpected results that are probative of nonobviousness are those that are "different in kind and not merely in degree from the results of the prior art." .... Results which differ by percentages are differences in degree rather than kind, where the modification of the percentage is within the capabilities of one skilled in the art at the time. Thus, where an unexpected increase in efficacy is measured by a small percentage, as here, and the evidence indicates that skilled artisans were capable of adjusting the percentage, the result constitutes a difference in degree, not kind. So too, where an increase by a percentage is expected but not found, that result is also likely only a difference in degree. In this case, the expected result was an increase, by some percentage, in the prevalence of certain side effects. The failure of that percent increase to materialize, though unexpected, constitutes only a difference in degree from the prior art results. Accordingly, the comparable tolerability of 0.1% and 0.3% adapalene does not indicate that the asserted claims are non-obvious.

Non-Probative Commercial Success

While the district court found evidence of commercial success in the fact that Tolmar and others had filed ANDA applications for the patented product, the Federal Circuit majority disagreed, noting:

The fact that Tolmar "believes that it can make a profit selling a generic version of the claimed invention" ... tells us very little about the level of commercial success of the patented invention relative to the prior art or the extent to which the commercial success of the branded drug is "due to the merits of the claimed invention."

While the district court found evidence of commercial success in the fact that the 0.3% product "quickly gained and maintained market share," the Federal Circuit majority determined that the commercial success was "of limited value in determining whether or not the presently asserted claims are obvious," because "market entry by others was precluded [due to blocking patents]," e.g., the Shroot patents.

Thus, the Federal Circuit reversed the district court and held "that claims 35 and 36 of the '181 patent, claims 24 and 27 of the '060 patent, claim 5 of the '558 patent, and claims 40 and 41 of the '044 patent are invalid as obvious."

Judge Newman's Dissent

Judge Newman filed a 17 page dissenting opinion that takes the majority to task for failing to give proper weight to the district court's factual findings and analysis, and "instead making their own findings, and applying flawed procedural and substantive law."

My colleagues do not identify clear error in the district court's findings; instead they distort the burdens of proof and production, ignore the applicable standard of proof and rely on their own factual determinations and creative theories of law, and eradicate the patent.

According to Judge Newman:

Particularly for close questions of patentability, the district court's findings and assessments of credibility and weight of evidence, and the district court's application of law to found facts, compel appellate attention. The role of the trial court in considering the evidence that each party provides through examination and cross-examination of witnesses and documents, with judicial elaboration and interaction, cannot be matched on appeal.

With regard to the analytical framework applied by the majority, and its burden-shifting, Judge Newman emphasized:

The district court correctly explained that "the proper analysis of obviousness under 35 U.S.C. §103 requires that 'all evidence relevant to obviousness or nonobviousness be considered, and be considered collectively,' without resortto presumptions of prima facie obviousness or burden-shifting.".... This is the correct standard, established in Graham v. John Deere and reiterated consistently and exhaustively.

Judge Newman presents a different view of the prior art, in a light indicating that the district court's determination was not clearly erroneous. With regard to Galderma's evidence of unexpected results, Judge Newman notes:

[B]ased on expert testimony from both sides, the district court found that "[w]hereas the prior art suggested a dose-dependent, clinically meaningful increase in side effects would result from increasing the concentration of adapalene from 0.03% to 0.1%, the claimed inventions achieved a difference in kind by discontinuing that trend." .... The district court explained that differences in degree occur when the invention is merely a continuation of a trend previously described in the prior art. ... Here, the prior art showed a trend to increased adverse side effects with increased concentration, while Galderma's products violated that trend. This was a difference in kind, not in degree.

The District Court's Legal Error?

The bulk of the majority decision does read like a de novo determination of validity. However, before Judge Prost commences her analysis of Galderma's objective evidence of non-obviousness, she notes this legal error in the district court's analysis:

Prior to addressing the obviousness of the asserted claims, we note an error in the district court's obviousness analysis. The district court framed the obviousness inquiry as requiring Tolmar to provide motivation in the prior art to triple the concentration of adapalene from 0.1% to 0.3%. ... Tolmar carried no such burden. .... Nothing in the statute or our case law requires Tolmar to prove obviousness by starting with a prior art commercial embodiment and then providing motivation to alter that commercial embodiment. .... This is particularly true where, as here, the prior art teaches a range that encompasses both the prior art commercial embodiment and the claimed invention.

Having found that the district court's determination rested on an incorrect legal footing, should the Federal Circuit have remanded the case for consideration under the proper legal framework?

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.